检索结果-内蒙古大学图书馆

Effectiveness of colorectal cancer screening integrating non-genetic and genetic risk: a prospective study based on UK Biobank data

引用

cancer Biology & Medicine 2024年第8期21卷 712-723页

作者： Yu Zhang Chao Sheng Zhangyan Lyu Hongji Dai Fangfang Song Fengju Song Yubei Huang Kexin Chen Department of Epidemiology and Biostatistics Key Laboratory of Molecular Cancer EpidemiologyKey Laboratory of Prevention and Control of Human Major DiseasesMinistry of EducationNational Clinical Research Center for CancerTianjin Medical University Cancer Institute and HospitalTianjin Medical UniversityTianjin 300060China

Objective: Few studies have evaluated the benefits of colorectal cancer(CRC) screening integrating both non-genetic and genetic risk factors. Here, we aimed to integrate an existing non-genetic risk model(Qcancer-10) and a 139-variant polygenic risk score to evaluate the effectiveness of screening on CRC incidence and ***: We applied the integrated model to calculate 10-year CRC risk for 430,908 participants in the UK Biobank, and divided the participants into low-, intermediate-, and high-risk groups. We calculated the screening-associated hazard ratios(HRs) and absolute risk reductions(ARRs) for CRC incidence and mortality according to risk ***: During a median follow-up of 11.03 years and 12.60 years, we observed 5,158 CRC cases and 1,487 CRC deaths, respectively. CRC incidence and mortality were significantly lower among screened than non-screened participants in both the intermediateand high-risk groups [incidence: HR: 0.87, 95% confidence interval(CI): 0.81±0.94;0.81, 0.73±0.90;mortality: 0.75, 0.64±0.87;0.70, 0.58±0.85], which composed approximately 60% of the study population. The ARRs(95% CI) were 0.17(0.11±0.24) and 0.43(0.24±0.61), respectively, for CRC incidence, and 0.08(0.05±0.11) and 0.24(0.15±0.33), respectively, for mortality. Screening did not significantly reduce the relative or absolute risk of CRC incidence and mortality in the low-risk group. Further analysis revealed that screening was most effective for men and individuals with distal CRC among the intermediate to high-risk ***: After integrating both genetic and non-genetic factors, our findings provided priority evidence of risk-stratified CRC screening and valuable insights for the rational allocation of health resources.

关键词： Colorectal cancer screening polygenic risk score incidence mortality

来源：评论

学校读者我要写书评

暂无评论

Lifetime risk of developing and dying from cancer in Henan Province,China:current status,temporal trends,and disparities

Journal of the National Cancer Center

引用

Journal of the National cancer Center 2025年第2期5卷 140-148页

作者： Qiong Chen Shuzheng Liu Yin Liu Hongwei Liu Hong Wang Lanwei Guo Huifang Xu Xiaoli Guo Xiaoyang Wang Ruihua Kang Liyang Zheng Shaokai Zhang Department of Cancer Epidemiology The Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer HospitalHenan Engineering Research Center of Cancer Prevention and ControlHenan International Joint Laboratory of Cancer PreventionZhengzhouChina

Objective:To understand the current status and changing trends in the lifetime risk of residents in Henan Province,China to develop and die from ***:Lifetime risk was estimated using the Adjusted for Multiple Primaries(AMP)method,incorporating cancer incidence,mortality,and all-cause mortality data from 55 cancer registries in Henan Province,*** were calculated overall and stratified by gender and *** annual percent change(APC)in lifetime risk from 2010 to 2020,stratified by gender and cancer site,was estimated using a log-linear ***:In 2020,the lifetime risk of developing and dying from cancer was 30.19%(95%CI:29.63%-30.76%)and 23.62%(95%CI:23.28%-23.95%),*** estimates were higher in men,with values of 31.22%(95%CI:30.59%-31.85%)for developing cancer and 26.73%(95%CI:26.29%-27.16%)for dying from cancer,compared with women,who had values of 29.02%(95%CI:28.12%-29.91%)and 20.08%(95%CI:19.51%-20.64%),*** were also geographical differences,with higher estimates in urban areas compared with rural *** had the highest lifetime risk of developing lung cancer,with a rate of 6.94%,followed by breast cancer(4.14%),stomach cancer(3.95%),esophageal cancer(3.75%),and liver cancer(2.86%).Similarly,the highest lifetime risk of dying from cancer was observed for the following sites:lung(5.99%),stomach(3.60%),esophagus(3.39%),liver(2.78%),and colorectum(1.55%).Overall,the lifetime risk of developing cancer increased,with an APC of 0.75%(P<0.05).Varying trends were observed across different cancer *** were gradual decreases in nasopharynx,esophagus,stomach,and liver ***,increasing trends were noted for most other sites,with the highest APCs observed in thyroid,prostate,lymphoma,kidney,and gallbladder ***:The lifetime risks of developing and dying from cancer were 30.19%and 23.62%,*** in cancer risk across different regions,genders,specific cancer s

关键词： Lifetime risk cancer Incidence Mortality Health policy China

来源：评论

学校读者我要写书评

暂无评论

An Outbreak of Serogroup Y Meningococcal Meningitis in a Private Secondary Vocational School-Guangzhou City,Guangdong Province,China,2023

引用

China CDC weekly 2024年第12期6卷 242-246,I0005页

作者： Xiang Zeng Qing He Yilan Li Yong Zhou Xiaoping Shao Pei Hu Jian Liang Yudan Song Chao Ma Lijie Zhang Limei Sun Lei Luo Chinese Field Epidemiology Training Program Chinese Center for Disease Control and PreventionBeijingChina Zhuhai Center for Disease Control and Prevention Zhuhai CityGuangdong ProvinceChina Guangdong Center for Disease Control and Prevention Guangzhou CityGuangdong ProvinceChina Guangzhou Center for Disease Control and Prevention Guangzhou CityGuangdong ProvinceChina Institute of Public Health Guangzhou Medical University&Guangzhou Center for Disease Control and PreventionGuangzhou CityGuangdong ProvinceChina Department of the National Immunization Programme Chinese Center for Disease Control and PreventionBeijingChina

What is already known about this topic?The inclusion of meningococcal vaccines in the National Immunization program(NIP)over several years has significantly reduced the incidence of meningococcal meningitis in China to historic ***,there has been a diversification of meningococcal serogroups,leading to a shift in dominant serogroups in China from serogroup A to serogroups C and B,accompanied by a rise in reports of serogroups Y and *** is added by this report?An outbreak of serogroup Y Neisseria meningitidis(Nm)in a secondary vocational school involved a single confirmed severe case and 24 individuals with laboratory-confirmed Nm *** investigation revealed that the outbreak was localized to the classroom of the confirmed *** close contact within a confined space was identified as a significant risk factor for Nm *** genotype sequence identified was type 1655(ST-1655),which is categorized under clonal complex 23(CC-23)and bears resemblance to 8 previously confirmed cases of serogroup Y meningococcal meningitis within Guangdong *** suggests that serogroup Y infections continue to sporadically emerge and have become prevalent *** are the implications for public health practice?This outbreak underscores the critical need to enhance surveillance of meningococcal serogroups and population carrier,and advocate for vaccination with MenY-containing vaccines.

关键词： break Secondary Guangdong

来源：评论

学校读者我要写书评

暂无评论

Analysis of Mortality and Life Expectancy Determinants Among 5,791 Deceased Pneumoconiosis Patients — Jiangsu Province, China, 2011–2023

引用

China CDC weekly 2024年第52期6卷 1417-1424页

作者： Hangju Zhu Lang Zhou Jinyi Zhou Lei Han Ming Wu Department of Epidemiology School of Public HealthNanjing Medical UniversityNanjing CityJiangsu ProvinceChina The Affiliated Cancer Hospital of Nanjing Medical University Nanjing CityJiangsu ProvinceChina Department of Occupation Disease Prevention and Cure Jiangsu Provincial Center for Disease Control and PreventionNanjing CityJiangsu ProvinceChina Department of Noncommunicable Chronic Disease Control and Prevention Jiangsu Provincial Center for Disease Control and PreventionNanjing CityJiangsu ProvinceChina

Pneumoconiosis is the occupational disease with the highest proportion in *** study conducted a retrospective analysis of 5,791 deceased pneumoconiosis *** this study,males comprised 93.02%of cases,with primary affected industries being mining(58.47%),manufacturing(20.55%),and public management(16.42%).Silicosis(69.42%)and coal worker’s pneumoconiosis(20.57%)were the predominant *** patients(66.47%)were diagnosed at stage *** differences were observed in both diagnosis age and post-diagnosis survival time across disease stages(P<0.05).The proportion of patients who died directly from lung infections was the highest(37.32%).The primary underlying causes of death in pneumoconiosis patients include pulmonary infections,cardiovascular and cerebrovascular diseases,and digestive tract and lung *** expectancy for patients aged 30–35 years was 15.83 *** excluding the effects of pulmonary infections,cardiovascular diseases,digestive tract tumors,and lung tumors,life expectancy increased by 3.75,1.11,1.31,and 0.63 years,*** patients with concurrent lung tumors showed a 7.797-fold increased mortality risk,while pulmonary infections elevated mortality risk by *** strategies for pneumoconiosis should emphasize both primary disease treatment and comprehensive care for complications,particularly pulmonary infections,cardiovascular diseases,and *** integrated approach could extend survival time and enhance quality of life for affected patients.

关键词： diagnosis mortality elevated

来源：评论

学校读者我要写书评

暂无评论

Prioritization of risk genes in colorectal cancer by integrative analysis of multi-omics data and gene networks

引用

Science China(Life Sciences) 2024年第1期67卷 132-148页

作者： Ming Zhang Xiaoyang Wang Nan Yang Xu Zhu Zequn Lu Yimin Cai Bin Li Ying Zhu Xiangpan Li Yongchang Wei Shaokai Zhang Jianbo Tian Xiaoping Miao Department of Epidemiology and Biostatistics School of Public HealthDepartment of Gastrointestinal OncologyZhongnan Hospital of Wuhan UniversityDepartment of Radiation OncologyRenmin Hospital of Wuhan UniversityTaiKang Center for Life and Medical SciencesWuhan UniversityWuhan 430071China Research Center of Public Health Renmin hospital of Wuhan UniversityWuhan UniversityWuhan 430060China Department of Cancer Epidemiology The Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer HospitalHenan Engineering Research Center of Cancer Prevention and ControlHenan International Joint Laboratory of Cancer PreventionZhengzhou 450008China Department of Gastrointestinal Surgery Renmin Hospital of Wuhan UniversityWuhan 430060China Department of Radiation Oncology Renmin Hospital of Wuhan UniversityWuhan 430060China Department of Gastrointestinal Oncology Hubei Cancer Clinical Study CenterZhongnan Hospital of Wuhan UniversityWuhan 430062China Department of Epidemiology and Biostatistics School of Public HealthTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430073China Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Medical UniversityNanjing 211166China

Genome-wide association studies(GWASs)have identified over 140 colorectal cancer(CRC)-associated loci;however,target genes at the majority of loci and underlying molecular mechanisms are poorly ***,we utilized a Bayesian approach,integrative risk gene selector(iRIGS),to prioritize risk genes at CRC GWAS loci by integrating multi-omics *** a result,a total of 105 high-confidence risk genes(HRGs)were identified,which exhibited strong gene dependencies for CRC and enrichment in the biological processes implicated in *** the 105 HRGs,CEBPB,located at the 20q13.13 locus,acted as a transcription factor playing critical roles in *** subsequent assays indicated the tumor promoter function of CEBPB that facilitated CRC cell proliferation by regulating multiple oncogenic pathways such as MAPK,PI3K-Akt,and Ras ***,by integrating a fine-mapping analysis and three independent case-control studies in Chinese populations consisting of 8,039 cases and 12,775 controls,we elucidated that rs1810503,a putative functional variant regulating CEBPB,was associated with CRC risk(OR=0.90,95%CI=0.86–0.93,P=1.07×10^(−7)).The association between rs1810503 and CRC risk was further validated in three additional multi-ancestry populations consisting of 24,254 cases and 58,741 ***,the rs1810503 A to T allele change weakened the enhancer activity in an allele-specific manner to decrease CEBPB expression via longrange promoter-enhancer interactions,mediated by the transcription factor,REST,and thus decreased CRC *** summary,our study provides a genetic resource and a generalizable strategy for CRC etiology investigation,and highlights the biological implications of CEBPB in CRC tumorigenesis,shedding new light on the etiology of CRC.

关键词： susceptibility genes gene screening models multi-omics GWAS CEBPB long-range promoter-enhancer interactions

来源：评论

学校读者我要写书评

暂无评论

Real-world lessons: combining cancer registry and retail pharmacy data for oral cancer drugs

引用

Journal of the National cancer Institute - Monographs 2024年第65期2024卷 162-167页

作者： Howlader, Nadia Lund, Jennifer L. Enewold, Lindsey Stevens, Jennifer Mcneel, Timothy Rivera, Donna Mariotto, Angela Cronin, Kathleen A. Surveillance Research Program Division of Cancer Control and Population Sciences National Cancer Institute Department of Epidemiology Gillings School of Global Public Health University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Healthcare Delivery Research Program Division of Cancer Control and Population Sciences National Cancer Institute Information Management Services Oncology Center of Excellence Food and Drug Administration

Background: Recent cancer care advances have introduced new oral therapies, and yet population registries lack detailed treatment data, hampering investigations into therapy uptake, adherence, and outcomes. Objective: This study aimed to assess the representativeness and completeness of linking Surveillance, epidemiology, and End Results (SEER) cancer registry data with data from two major retail pharmacy chains, collectively covering a large segment of the US market. Methods: A deterministic data linkage between 11 SEER cancer registries and retail pharmacy data (excluding mail order fills) was conducted for individuals diagnosed with selected cancers from 2013 to 2017, with follow-up through 2019. Descriptive characteristics of the linked and unlinked populations were examined. In a selected subcohort of older women (aged ≥65) with first and only primary breast cancer who had Medicare Part D claims for tamoxifen, we further validated the linkage using Medicare Part D event data as the reference standard. Results: Among 758 068 eligible individuals, only 6.4% were linked to CVS/Walgreens data;the linkage percentage varied by age, sex, race, ethnicity, registry, and cancer type. Within the subcohort of 5963 older women with breast cancer and a claim for tamoxifen in Part D data, 25% were identified as tamoxifen users in retail pharmacy data. Out of these 1490 women, 749 (50.3%) had complete longitudinal tamoxifen dispensing information from retail pharmacy data. Conclusion: Retail pharmacy data show promise in identifying oral anticancer treatments, enhancing SEER registry efforts, but they require further validation. We propose an evaluation framework, sharing insights and potential use cases for this resource. © 2024 Published by Oxford University Press.

关键词：

来源：评论

学校读者我要写书评

暂无评论

Landscape analysis of environmental data sources for linkage with SEER cancer patients database

引用

Journal of the National cancer Institute - Monographs 2024年第65期2024卷 132-144页

作者： Tatalovich, Zaria Chtourou, Amina Zhu, Li Dellavalle, Curt Hanson, Heidi A. Henry, Kevin A. Penberthy, Lynne Surveillance Research Program Division of Cancer Control and Population Sciences National Cancer Institute Rockville MD United States Computational Sciences and Engineering Division Oak Ridge National Laboratory US Department of Energy Oakridge TN United States Temple University Philadelphia PA United States Cancer Prevention and Control Fox Chase Cancer Center Philadelphia PA United States

One of the challenges associated with understanding environmental impacts on cancer risk and outcomes is estimating potential exposures of individuals diagnosed with cancer to adverse environmental conditions over the life course. Historically, this has been partly due to the lack of reliable measures of cancer patients' potential environmental exposures before a cancer diagnosis. The emerging sources of cancer-related spatiotemporal environmental data and residential history information, coupled with novel technologies for data extraction and linkage, present an opportunity to integrate these data into the existing cancer surveillance data infrastructure, thereby facilitating more comprehensive assessment of cancer risk and outcomes. In this paper, we performed a landscape analysis of the available environmental data sources that could be linked to historical residential address information of cancer patients' records collected by the National cancer Institute's Surveillance, epidemiology, and End Results program. The objective is to enable researchers to use these data to assess potential exposures at the time of cancer initiation through the time of diagnosis and even after diagnosis. The paper addresses the challenges associated with data collection and completeness at various spatial and temporal scales, as well as opportunities and directions for future research. © 2024 The Author(s). Published by Oxford University Press. All rights reserved.

关键词：

来源：评论

学校读者我要写书评

暂无评论

The global progress and quality assessment of research on the association between circulating tumor DNA and clinical prognosis:a systematic review

Journal of the National Cancer Center

引用

Journal of the National cancer Center 2025年第2期5卷 156-166页

作者： Meng Zhang Xiaowei Chen Qingxin Zhou Nana Guo Baoshan Cao Hongmei Zeng Wanqing Chen Feng Sun Department of Epidemiology and Biostatistics School of Public HealthPeking UniversityBeijingChina Key Laboratory of Epidemiology of Major Diseases(Peking University) Ministry of EducationBeijingChina Tianjin Centers for Disease Control and Prevention TianjinChina Hebei Centers for Disease Control and Prevention ShijiazhuangChina Department of Medical Oncology and Radiation Sickness Peking University Third HospitalBeijingChina National Central Cancer Registry National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Office of Cancer Screening National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Xinjiang Medical University UrumqiChina

Objective:Circulating tumor DNA(ctDNA)has shown potential as a prognostic biomarker in patients with solid *** study aimed to systematically summarize the global application of ctDNA in the prognostic man-agement of solid tumor patients and to evaluate the quality of the current ***:PubMed,Web of Science,Embase,Cochrane Library,Scopus,and clinical *** databases were searched to collect cohort studies on ctDNA in the prognosis of solid tumor patients from January 2016 to May *** language was limited to *** including general information,participants and cancer characteristics,ctDNA and outcome information were *** quality of the studies was assessed using the Newcastle-Ottawa Scale ***:A total of 214 studies were included in the final analysis,encompassing 21,076 *** number of studies has increased annually from 2016 to *** most common types of solid tumors studied were colorectal cancer(27.10%),lung cancer(20.09%),pancreatic cancer(16.82%),and breast cancer(14.02%).The top three journals by number of publications had an impact factor in 2023 greater than *** the studies,the median sample size was 69(interquartile range:41-111),69.81%had a sample size<100,68.92%had a median/mean age≥60 years,and 74.05%were from developed ***-center studies accounted for 40.36%.Additionally,29.82%of the studies had a bias risk score≤*** 16.67%of studies on liver cancer had a bias risk score>*** primary criteria not met by the studies included“Adequacy of follow-up of cohorts”(33.33%),“Assessment of outcome”(32.16%)and“Representativeness of the exposed cohort”(27.49%).Conclusions:The prognostic value of ctDNA in patients with solid tumors is gaining increasing attention,leading to a steady rise in the number of ***,many studies still suffer from small sample sizes and a lack of ***,details regarding ctDNA detection methods and results reporting

关键词： Circulating tumor DNA Solid tumor Prognosis Overall survival

来源：评论

学校读者我要写书评

暂无评论

Circulating tumor DNA as prognostic markers of relapsed breast cancer:a systematic review and meta-analysis

引用

Journal of the National cancer Center 2024年第1期4卷 63-73页

作者： Na’na Guo Qingxin Zhou Xiaowei Chen Baoqi Zeng Shanshan Wu Hongmei Zeng Feng Sun Hebei Province Centers for Disease Control and Prevention ShijiazhuangChina Tianjin Centers for Disease Control and Prevention TianjinChina Department of Epidemiology and Biostatistics School of Public HealthPeking UniversityBeijingChina Department of Science and Education Peking University Binhai HospitalTianjinChina Clinical Epidemiology and EBM Unit National Clinical Research Center for Digestive DiseasesBeijing Friendship HospitalCapital Medical UniversityBeijingChina National Central Cancer Registry National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Key Laboratory of Major Disease Epidemiology Ministry of Education(Peking University)BeijingChina

Objective: Circulating tumor DNA (ctDNA) is increasingly being used as a potential prognosis biomarker in patients of breast cancer. This review aims to assess the clinical value of ctDNA in outcome prediction in breast cancer patients throughout the whole treatment cycle. Methods: PubMed, Web of Science, Embase, Cochrane Library, Scopus, and clinical *** were searched from January 2016 to May 2022. Conference abstracts published in last three years were also included. The following search terms were used: ctDNA OR circulating tumor DNA AND breast cancer OR breast carcinoma. Only studies written in English languages were included. The following pre-specified criteria should be met for inclusion: (1) observational studies (prospective or retrospective), randomized control trials, case-control studies and case series studies;(2) patients with breast cancer;(3) ctDNA measurement;(4) clinical outcome data such as objective response rate (ORR), pathological complete response (pCR), relapse-free survival (RFS), overall survival (OS), and so on. The random-effect model was preferred considering the potential heterogeneity across studies. The primary outcomes included postoperative short-term outcomes (ORR and pCR) and postoperative long-term outcomes (RFS, OS, and relapse). Secondary outcomes focused on ctDNA detection rate. Results: A total of 30 studies, comprising of 19 cohort studies, 2 case-control studies and 9 case series studies were included. The baseline ctDNA was significantly negatively associated with ORR outcome (Relative Risk [RR] = 0.65, 95% confidence interval [CI]: 0.50–0.83), with lower ORR in the ctDNA-positive group than ctDNAnegative group. ctDNA during neoadjuvant therapy (NAT) treatment was significantly associated with pCR outcomes (Odds Ratio [OR] = 0.15, 95% CI: 0.04–0.54). The strong association between ctDNA and RFS or relapse outcome was significant across the whole treatment period, especially after the surgery (RFS: Hazard Ratio [HR]

关键词： ctDNA Breast cancer Prognostic outcome prediction Meta-analysis

来源：评论

学校读者我要写书评

暂无评论

Global burden of thyroid cancer in 2022:Incidence and mortality estimates from GLOBOCAN

引用

Chinese Medical Journal 2024年第21期137卷 2567-2576页

作者： Zhangyan Lyu Yu Zhang Chao Sheng Yubei Huang Qiang Zhang Kexin Chen Department of Epidemiology and Biostatistics Key Laboratory of Molecular Cancer EpidemiologyKey Laboratory of Prevention and Control of Human Major DiseasesMinistry of EducationNational Clinical Research Center for CancerTianjin Medical University Cancer Institute and HospitalTianjin Medical UniversityTianjin 300060China Department of Maxillofacial and Otorhinolaryngology Oncology National Clinical Research Center for CancerKey Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and HospitalTianjin 300060China

Background:Thyroid cancer(TC)is the most common malignancy of the endocrine *** study aimed to assess the global distribution of TC incidence and mortality in 2022,as well as to predict the burden for the year ***:Data from the GLOBOCAN 2022 database were used to analyze the age-standardized incidence and mortality rates of TC by sex,age group(<55 years and≥55 years),country,world region,and level of Human Development Index(HDI)for 185 *** predicted incidence and mortality burden for 2050 was calculated based on demographic ***:In 2022,an estimated 821,214 new TC cases and 47,507 TC-related deaths occurred *** age-standardized incidence rates(ASIRs)and age-standardized mortality rates(ASMRs)were higher in women(ASIR:13.60 per 100,000;ASMR:0.53 per 100,000)than in men(ASIR:4.60 per 100,000;ASMR:0.35 per 100,000).The ASIR in high HDI countries was approximately ten times higher than that in low HDI countries for both sexes,with relatively similar ASMR across *** 185 countries,China had the largest number of TC cases(accounting for 56.77% of total cases)and TC-related deaths(accounting for 24.35% of global TC-related deaths),with the highest ASIR in men(13.30 per 100,000).Worldwide,approximately 64.63% of TC cases occurred in populations under 55 years old,while nearly 82.99% of TC-related deaths occurred in populations aged 55 years and *** the rates stay the same as in 2022,it is projected that approximately 1,100,000 new TC cases and 91,000 TC-related deaths will occur in 2050,indicating a 34.15% and 89.58% increase,***:TC is a highly frequent cancer worldwide with disparities across regions,genders,and age *** results provide light on the worldwide TC disease burden and facilitate regionally customized prevention measures.

关键词： Thyroid cancer Incidence Mortality Trend analysis GLOBOCAN 2022

来源：评论

学校读者我要写书评

暂无评论

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案：

请选择收藏分类：

通借通还

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：